28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Dec
VELO
Gennemgang og analyse af Veloxis' søgsmålJeg har brugt min aften på at "hygge" mig med Veloxis netop..
67
20 Dec
 
Det er meget velbeskrevet i talrige bøger og artikler, at tilstandene i store dele af verden udenfor..
49
18 Dec
VWS
Normal 0 21 false false false DA X-NONE X-NONE ..
30
18 Dec
GEN
Med FDA´s godkendelse af Amgens (Micromet) godkendelse af Blincyto (blinatumomab), fik vi for alvor ..
27
18 Dec
PNDORA
Nu har jeg købt og solgt aktier i 8 år og var os her på debatten for 4-5 år siden men har glemt mit ..
24
18 Dec
 
  Jeg er gratist, jeg læser med på EI uden at skrive. Det er sjældent, man kan få gratis lunch; men ..
13
21 Dec
MY
Det er jo en ejendommelig debat, der er kommet ud af det spørgsmål. Der er jo ingen, der nogensinde ..
11
15 Dec
GEN
Genmab har afholdt bestyrelsesmøde og valgt at give bestyrelse, direktion og ledende medarbejdere op..
11
20 Dec
VWS
Det er nemt at lave en hurtig statistik over perioden fra medio December til medio Januar, på basis ..
10
20 Dec
VWS
Kære Mena: Her definationen af et JV: http://da.wikipedia.org/wiki/Joint_venture   "Parterne er også..
10

Tech Companies Send Criticism Along With NSA-Related Data -- Update

04/02/2014 00:06:00
By Danny Yadron Technology companies including Google Inc. and Microsoft Corp. released new figures on the amount of data requests they received from U.S. ..

U.S. Hot Stocks: Hot Stocks to Watch

03/02/2014 14:07:00
Among the companies with shares expected to actively trade in Monday's session is Herbalife Ltd. (HLF). Herbalife Ltd. (HLF) raised its fourth-quarter outl..

Pfizer Study Meets Primary Endpoints

03/02/2014 13:05:00
Pfizer Inc. (PFE) said Monday that a Phase 2 trial of its advanced breast cancer treatment met its primary endpoint. Pfizer said a study comparing the effec..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
EAM Solar ASA : Minutes from EGM 19 December 2014
2
Delta Lloyd requests court ruling on DNB measures
3
Soitec updates its 2015 and 2016 financial guidance
4
TiGenix submits its pivotal US trial design for Cx601 to the FDA for Special Protocol Assessment
5
Lundbeck to research link between immune system and brain diseases

Copyright Euroinvestor A/S 2014   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 December 2014 10:32:50
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20141219.2 - EUROWEB1 - 2014-12-22 11:32:50 - 2014-12-22 10:32:50 - 1000 - Website: OKAY